Exchange: NASDAQ·Updated 07:37 PM EDT

MDXG Earnings

Latest Earnings Results: Q3 '26

Reported: Oct 28

Estimated EPS

$0.00

Reported EPS

-$0.06

Surprise

-21528.57%

Estimated Rev

$68.56M

Reported Rev

$62.28M

Surprise

-9.16%

• Reported GAAP EPS of -$0.01 down -106.67% YoY • Reported revenue of $62.28M down -45.23% YoY • MiMedx expects 2026 net sales of $250 to $260M, fourth-quarter Adjusted EBITDA sequentially higher than the third quarter, and longer-term annual net sales growth in the low double-digits with adjusted EBITDA margin above 20%.

Bullish Takeaway

MiMedx recorded 9% year-over-year Surgical sales growth and nearly two-thirds of sales from Surgical, obtained a favorable AXIOFILL court ruling, and entered a $25M patent license agreement.

Bearish Takeaway

MiMedx faced a 71% year-over-year Wound sales decrease amid Medicare reimbursement changes, lower total sales and a net loss, plus FTC review and completion risks for Sanara.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
$0.02
--
--
N/A
Q3 '26
$0.00
-$0.06
-21528.57%
MISSED
Q2 '26
-$0.05
-$0.10
-102.02%
MISSED
Q1 '26
-$0.03
-$0.07
-179.33%
MISSED
Q4 '25
$0.09
$0.10
13.21%
BEAT

Advertisement|Remove ads.